Phesi launches AI-driven trial accelerator, saving $7m per trial
Yesterday, global provider of patient-centric data analytics, Phesi launched its AI-driven Trial Accelerator Platform, an integrated SaaS solution designed to enable clinical development personnel to leverage study and control arm data, so as to accelerate product development.
The platform’s methods and AI models have been created and validated over the past 15 years of Phesi’s work. The Trial Accelerator Platform brings together real-world data from over 60 million patients and 485,000 clinical trial records, and will facilitate real-time scenario modelling across patient, endpoint, country, KOL, and investigator site allocation (reducing non-active, non-enrolling sites to under 10%).
Furthermore, by making trials faster and cheaper, it is believed the platform could save sponsors up to $7million per phase 3 trial through a reduction in protocol amendments.
Industry data shows that the average phase 3 trial protocol experiences 3.3 substantial amendments: by simulating trial outcomes, Phesi’s AI platform aims to improve the overall probability of trial success, avoiding such changes – and thereby saving c. $500k per amendment (up to $1.5million per trial).
The platform also permits time saving, avoidance of amendments resulting in a reduction in the 5.2 months cumulative implementation time for those protocol amendments normally being made.
Chief operating officer at Phesi, Jonathan Peachey commented: “We can eradicate the reliance on ‘gut feel’ or past experience that defines much decision making in clinical development today. Phesi makes sure companies learn from the past by simulating the future, by delivering simulated clinical trial outcomes with AI-powered patient-centric data science.”
The Trial Accelerator Platform should also improve patient centricity throughout clinical development and commercialisation. Currently, a comprehensive and/or consistent view of the patient throughout a trial is lacking. By deploying digital twins and digital control arms (DCAs), and creating digital patient profiles, Phesi’s AI-platform is thought to drive further innovation and relieve patient and site burden.
The AI-platform’s targeted users are heads of development, medical directors, clinical and portfolio leads, heads of medical affairs, value and outcome research teams, and feasibility groups. It will launch with four key modules: patient profile view, trial performance view, country performance view, and investigator site performance view.
Phesi’s CEO and founder, Dr Gen Li, said: “The industry needs a way to build the bridge between data and insight to deliver truly patient-centric trials. After years of upheaval from Covid-19 and with global events having huge impact on clinical development, being able to predict outcomes and minimise both risk and impact on patients is critical.”
“The pandemic has also shown us what the biopharmaceutical industry is capable of when we work at speed. We need to replicate this approach in other areas of development and commercialisation through the use of data analytics and technology,” he continued.
Phesi’s AI-platform joins a growing body of digital technologies endeavouring to ameliorate clinical trials, for both patients and the industry.